Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

US DOD to commence new trial with Pluristem's PLX-R18 cell therapy against ARS Pluristem Therapeutics stated that a pilot study of its PLX-R18 cell therapy will be initiated by the US Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI), part of the Uniformed Services University of Health Sciences (USU).
Contract Research & Services > Clinical Trials > News
Mateon’s ovarian cancer treatment CA4P shows favorable results in Focus study By PBR Staff Writer
Mateon Therapeutics’ ovarian cancer treatment CA4P in combination with Roche’s bevacizumab (Avastin) has showed favorable results in the scheduled interim analysis of the ongoing phase 2/3 Focus study.
Contract Research & Services > Clinical Trials > News Aradigm gets NIH grant for Linhaliq in pulmonary non-tuberculous mycobacteria treatment The National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) have awarded a Small Business Initiative Research (SBIR) grant to Aradigm to study the treatment of two pulmonary non-tuberculous mycobacteria (PNTM) infections, Mycobacterium avium and Mycobacterium abscessus, with the company’s inhaled liposomal ciprofloxacin products Linhaliq and Lipoquin.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
FDA lifts clinical hold on study of Multikine for head and neck cancer
By PBR Staff Writer
The US Food and Drug Administration (FDA) has lifted the clinical hold it had imposed on the CEL-SCI and Ergomed co-developed Multikine’s phase 3 head and neck cancer study.
Contract Research & Services > Clinical Trials > News
BMS’ kidney cancer drug met co-primary endpoint in CheckMate trial
By PBR Staff Writer
Bristol-Myers Squibb’s (BMS) kidney cancer drug Opdivo in combination with Yervoy (ipilimumab) has met the co-primary endpoint of objective response rate (ORR) against sunitinib in CheckMate -214 trial.
Contract Research & Services > Clinical Trials > News
Ophthotech’s wet-AMD drug Fovista fails in phase 3 AMD trial
By PBR Staff Writer
Ophthotech’s anti-PDGF therapy Fovista (pegpleranib) for treating wet age-related macular degeneration (AMD) has failed to meet the primary endpoint in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
Heron initiates phase 3 program for HTX-011 in postoperative pain
Heron Therapeutics has reported positive outcome of a recent End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) regarding its investigational agent, HTX-011, to prevent postoperative pain for the first 72 hours post surgery.
Contract Research & Services > Clinical Trials > News
Allegro’s Luminate succeeds in phase 2 diabetic macular edema trial
By PBR Staff Writer
Allegro Ophthalmics' Luminate integrin peptide therapy has passed a phase 2 trial in diabetic macular edema (DME) patients by meeting its primary endpoint when used as a sequential treatment.
Contract Research & Services > Clinical Trials > News
Cancer Research UK, Biotecnol to begin trials of novel immuno-oncology treatment
By PBR Staff Writer
Cancer Research UK has collaborated with Biotecnol to start early phase clinical trials for new immuno-oncology treatment, Tb535H.
Contract Research & Services > Clinical Trials > News
Zynerba’s cannabis-based epilepsy gel fails in phase 2 trial
By PBR Staff Writer
Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial.
Contract Research & Services > Clinical Trials > News
Lilly’s migraine drug Lasmiditan succeeds in second phase 3 trial
By PBR Staff Writer
Eli Lilly's migraine drug Lasmiditan has met its primary endpoint in a second phase 3 trial.
Contract Research & Services > Clinical Trials > News
Orbsen gets European approval to start diabetic kidney disease trial for Obrcel-M
Orbsen Therapeutics’ stromal cell immunotherapy, OBRCEL-M has been approved to begin testing in a randomised, double blind, and placebo-controlled clinical trial in Europe to treat diabetic kidney disease.
Contract Research & Services > Clinical Trials > News
Flex Pharma launches ALS phase 2 study with FLX-787 in US
Flex Pharma has initiated a Phase 2 randomized, controlled, double-blinded, parallel design trial in the US.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests